Persistent Systems Ltd. share price target

Persistent sustained its ‘consistent compounding’ narrative for another quarter with 4.1% q/q and 17.3% y/y CC revenue growth to $423mn aided by a healthy order book along with (LTM TCV up 14.2% y/y) continued deepening of its large-client relationships.

Consistent growth engine with strong deal visibility: Persistent continues to demonstrate a structurally strong growth profile (+4.1% QoQ CC) and robust booking momentum. Rising TCV (US$674.5 mn - up 11% QoQ/13.5% YoY) and ACV (US$501.9 mn - up 12% QoQ/17% YoY) reflects improving revenue visibility, driven by deeper participation in large, strategic client programs. Demand remains healthy across verticals, supported by application and data modernization themes in BFSI and healthcare. The management noted that it remains firmly on track toward its US$2 bn revenue aspiration by FY27,...

Persistent Systems’ (PSYS) strong revenue growth of 4.1% QoQ CC in a furlough quarter (Q3FY26) was aided by an increase in software license sales (up 44% QoQ USD) and healthy growth in services business (+2.6% QoQ USD).

Inline revenue. Margin surprise on sale of AI Software licenses. The US$2bn FY27 goal may require an acquisition

Persistent Systems (PSYS) reported a 3QFY26 revenue of USD422m (vs. est. USD420m), up 4.0% QoQ in USD terms and 4.1% in CC (est. +3.5%). Adj. EBIT margin stood at 16.7% (est. 15.0%).

PSYS’ revenue growth of 4.2% QoQ CC was ahead of our optimistic estimates. Growth was led by the BFSI and technology verticals. Healthcare vertical has improved, post two quarters of muted growth from client-specific offshoring.

Revenue stood at INR 35,807 Mn, up 7.4% QoQ and 23.6% YoY, outperforming our estimate by ~2.7%, driven by consistent client additions and higher offshore volumes.

2QFY26 performance was strong. Growth leader among the Tier-2. And very consistent. Margins outperformed on lower Software cost

AI-Led Transformation for long-term differentiation: Persistent's AI-led transformation through its Sasva platform (filed 20 new patents), enterprise AI readiness offerings, & internal AI deployments is a key differentiator. With 50+ AI agents deployed & partnerships with Anthropic, the company is also embedding AI across delivery, legal, HR, finance, & supply chain. This positions Persistent well to capture next-gen digital transformation opportunities, drive...

We maintain our BUY rating on the stock.

Persistent Systems (PSYS) reported 2QFY26 revenue of USD406m (vs. est. USD404m), up 4.2% QoQ in USD terms and 4.4% in CC (est. +3.5%). EBIT margin stood at 16.3% (est. 15.7%).

Revenue: Persistent Systems Q1FY26 revenue came in at INR 33,336 Mn, up 21.8% YoY (+2.8% QoQ), in-line with our estimates, primarily driven by robust performance in the BFSI segment, with incremental contributions from Software, Hi-Tech, and Emerging Markets verticals, partially offset by softness in healthcare and Life Sciences.

We resume our coverage with a BUY rating on the stock.

Revenue stood at $389.7 million, up 3.3% q-o-q in CC terms, missing our 4% estimate. EBIT margins declined ~10 bps q-o-q to 15.5%, missing our estimate of 15.9%.

CC QoQ revenue growth at 3.3% was a tad soft. The company talked about delayed decision making and delayed ramp ups to be reasons

The revenue performance (+3.3% QoQ) was tad below our estimates (+3.5% QoQ CC), margins at 15.5% were also slightly below our estimates of 15.7%. The momentum within BFSI and Hi-Tech continued, while Healthcare growth decelerated further and reported a decline of 1.9%. The delayed ramp up and right-shifting of resources have led to the decline in Healthcare vertical. The...

Persistent Systems (PSYS) reported 1QFY26 revenue of USD390m (vs. est. USD392m), up 3.9% QoQ in USD terms and 3.3% in CC (est. +4.0%). EBIT margin stood at 15.5% (est. 15.8%).

We interacted with management of Persistent Systems to understand the company’s business strategy and growth prospects.

Delivers industry leading growth in FY25 and in 4QFY25 and maintains its aspiration of US$2bn revenue by FY27 (20% CAGR)